Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Apr 18;8:e2300495. doi: 10.1200/PO.23.00495

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FIG 1. — Expression of PARP1 immunohistochemistry. (A) Intensity 1, extent 5%, ×40 (upper right, ×200). No PARP1 expression in tumor compared with internal control (positively stained lymphocytes; lower right, ×200) focal area of PARP1 expressing tumors with intensity 1. (B) Intensity 2, extent 95%, ×40 (right, ×200) strong PARP1 expression in most tumor cells, but the intensity is lower than internal control (positively stained lymphocytes). (C) Intensity 3, extent 100%, ×40 (right, ×200) strong PARP1 expression in all tumor cells, the intensity is same or slightly lower than internal control (positively stained lymphocytes). (D) Scatter dot plots showing PARP1 score by histology (left) and response to chemotherapy (right). * P < .05. CR, complete response; LCNEC, large cell neuroendocrine carcinoma; PARP1, poly (ADP-ribose) polymerase-1; PD, progressive disease; PR, partial response; SCLC, small cell lung cancer; SD, stable disease.